Ten63
Leveraging advanced AI and physics-based models to design breakthrough drugs for cancer and other diseases once thought impossible to treat
Ten63 Therapeutics is focused on improving human health by developing better, more durable therapeutics against cancer and some of the world’s most lethal diseases. We are leveraging our proprietary in silico platform BEYOND to generate novel therapeutics to hit previously undruggable targets while bringing the paradigm of durable response into early drug design through our unique ability to predict and overcome drug resistance.
Testimonial
Related Companies
Klona Biotech
The future of human tissue replacements using 3D printing
London, United Kingdom
Lyric Bio
Pioneering the future of biomanufacturing using proven and proprietary 3D bioprinting and tissue engineering technologies
San Carlos, California
Eywa Biotech
Scaling the production of pharmaceutical-grade psychedelic compounds through synthetic biology
Montevideo, Uruguay · Buenos Aires, Argentina
PrettyLitter
Develops a lightweight cat litter that helps cat owners monitor their pets' health by changing colors in response to abnormalities in urine.
Los Angeles, United States
nVision
nVision’s focus is on women’s health. The company created the first FDA-cleared device for collecting cells from the fallopian tubes, which aimed to enable earlier diagnosis of ovarian cancer. In 2018, nVision was acquired by Boston Scientific.
Senodia
MEMS sensors for various applications.
China, Shanghai
Aanika
Innovative science-backed insurance solutions for agriculture and food industries with Bio technology.
Brooklyn, United States
